In this article, we report an APW closure with a symmetric membranous ventricular septal defect (VSD) occluder device without forming an arteriovenous loop.
The procedure was performed under general anesthesia. The 4Fr and 5Fr sheaths were located into the right femoral artery and right femoral vein, respectively. Unfractionated heparin (100 U/kg) was administered intravenously. The mean aorta and pulmonary artery pressures were 48 and 33 mmHg, respectively. An aortic root angiography was performed using a pigtail catheter, which revealed a 5.1-mm APW located 8-mm away from the left coronary artery. This diameter was compatible with that measured by transthoracic echocardiography. The defect was crossed via the antegrade route from the pulmonary artery to the aorta using a 5Fr Judkins right coronary catheter (Medtronic Inc., Minneapolis, MN, USA) with an angled tip of 0.035-inch hydrophilic guidewire. The wire was advanced through the descending aorta and exchanged by a 0.035-inch stiff wire. Over this wire, a 6Fr CeraTM membranous VSD occluder delivery system (Lifetech Scientific Medical Co. Ltd., Shenzhen, China) was advanced through the femoral vein and APW into the descending aorta. A 7-mm symmetric membranous VSD occluder (CeraTM; Lifetech Scientific Medical Co. Ltd., Shenzhen, China) device was advanced to descending aorta through the 6Fr delivery system. After the first disc was opened in the aorta and the entire system was withdrawn to the pulmonary side of the defect, the second disc was opened under fluoroscopic and transthoracic echocardiographic guidance. As the control aortography and echocardiography showed no protrusion into the aortic and pulmonary sides, no residual shunt and no compression on the left coronary artery ostium, the device was released and the defect was occluded successfully (Figure 2, Video 1). The total procedural time was 40 min and the total fluoroscopy time was 3.5 min. On control echocardiography on the following day, there was no residual shunt (Video 2). The patient received antibiotherapy before and after the procedure. Acetylsalicylic acid was advised at a dose of 3 mg/kg/day for three months, and the infant was discharged on Day 3 of the procedure. At onemonth follow-up, the infant gained 600 g and the dilatation in the left heart cavities regressed. The patient has been under follow-up for one year without any complications.
Video: Video showing minimally invasive total arterial off-pump coronary revascularization.
Video: Video showing minimally invasive total arterial off-pump coronary revascularization.
The proximal and distal type small APW can be closed by the ADO? II additional sizes. This device seems to be suitable for the PC of small defects (<4 mm) in close proximity to pulmonary bifurcation, aortic valve and/or coronary ostium, thanks to its smaller disc size, which minimizes the risk of obstruction of vessel lumen, semilunar valve, and left coronary artery.[7,8] A lternatively, Odemis et al.[10] used a 7-mm Nit-Occlud® P DA-R d evice ( BVM M edical L td., Leicestershire, UK) and successfully closed the APW, type I defect of 5 mm, in a three-month-old patient. They offered this device owing to its lower profile, requiring smaller sheet sizes, and the completely flat retention disk. Despite limited experiences, its small skirt at the distal side and very flat design may provide the advantage of reducing the risk of compression on the coronary arteries.
The type, size, and location of the defect, suitability of the device to be selected, and the body weight of the infant are critical factors in the selection of an appropriate device. The ideal device for PC of APW should be double-disc with a short waist and short skirt rim, thereby, reducing the risk of protrusion into the pulmonary artery and compression of coronary artery and requiring a small sheath. Therefore, in the present case, we preferred a 7-mm symmetric membranous VSD occluder device (waist length: 3 mm, right disc: 11 mm and left disc: 11 mm) through its short waist and two equal and short retention discs (only 2 mm for each side) and the device was fitted to the defect. After the procedure, we observed no residual shunt or complications such as protrusion into the pulmonary vessels or compression onto the coronary arteries. In addition, requirement of a small 6Fr sheath prevented the damage to the small vessels of the infant.
During the procedure, we passed directly from the antegrade route using a soft hydrophilic guidewire and a 5Fr right Judkins catheter from pulmonary artery to ascending aorta. This technique facilitated the procedure and the procedure completed without using a snare in a short time. In our technique, we used only 4Fr sheath in the arterial side and we used the arterial way to show defect before and after releasing the device. Of note, the interventional cardiologist should know the properties of the materials at shelf and choose the most appropriate one according to each individual case. In addition, a flexible strategy should be followed according to the characteristics of the case and the easiest and simplest way should be preferred, particularly in infants.
In conclusion, it is challenging to choose the appropriate device and, to date, there is no consensus on the choice of an optimal device for aortopulmonary window closure. The intermediate type, as in our patient, consists of a central defect with adequate superior and inferior rims, which makes it most suitable for percutaneous closure. We recommend the symmetric membranous ventricular septal defect occluder and antegrade passing technique as a safe and effective alternative to surgery for percutaneous closure of aortopulmonary window in infants with large defects soon after the diagnosis.
Declaration of conflicting interests
The authors declared no conflicts of interest with respect to
the authorship and/or publication of this article.
Funding
The authors received no financial support for the research
and/or authorship of this article.
1) Jacobs JP, Quintessenza JA, Gaynor JW, Burke RP,
Mavroudis C. Congenital Heart Surgery Nomenclature and
Database Project: aortopulmonary window. Ann Thorac
Surg 2000;69(4 Suppl):S44-9.
2) Stamato T, Benson LN, Smallhorn JF, Freedom RM.
Transcatheter closure of an aortopulmonary window
with a modified double umbrella occluder system. Cathet
Cardiovasc Diagn 1995;35:165-7.
3) Campos-Quintero A, García-Montes JA, Zabal-Cerdeira C,
Cervantes-Salazar JL, Calderón-Colmenero J, Sandoval JP.
Transcatheter device closure of aortopulmonary window. Is
there a need for an alternative strategy to surgery? Rev Esp
Cardiol (Engl Ed) 2019;72:349-51.
4) Trehan V, Nigam A, Tyagi S. Percutaneous closure of
nonrestrictive aortopulmonary window in three infants.
Catheter Cardiovasc Interv 2008;71:405-11.
5) Sabnis GR, Shah HC, Lanjewar CP, Malik S, Kerkar PG.
Transcatheter closure of large aortopulmonary window in a
neonate. Ann Pediatr Cardiol 2018;11:228-30.
6) Pillekamp F, Hannes T, Koch D, Brockmeier K,
Sreeram N. Transcatheter closure of symptomatic
aortopulmonary window in an infant. Images Paediatr
Cardiol 2008;10:11-7.
7) Uçar T, Karagözlü S, Ramoğlu MG, Tutar E. Transcatheter
closure of aortopulmonary window with Amplatzer duct
occluder II: additional size. Cardiol Young 2020;30:424-6.
8) Fiszer R, Zbro?ski K, Szkutnik M. Percutaneous closure of
an aortopulmonary window using Amplatzer Duct Occluder
II: Additional Sizes: the first reported case. Cardiol Young
2017;27:812-5.